Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

Stock Information for Medicenna Therapeutics Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medicenna Therapeutics Corp.

Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
Medicenna Therapeutics Announces Participation in Upcoming Conferences
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
Medicenna Announces Changes to Board Composition
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.